ORM-6151

N/A

Report date: 2024/05/20 17:02:31
First In Class

Base Information

Drug NameORM-6151
Drug Alias NameORM-6151BMS-986497
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > β-glucuronide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SMol006 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEukaryotic peptide chain release factor GTP-binding subunit ERF3A degradersAnti-Myeloid cell surface antigen CD33
TargetsEukaryotic peptide chain release factor GTP-binding subunit ERF3AMyeloid cell surface antigen CD33
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrum Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb Company
Inactive CompaniesOrum Therapeutics Inc
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A